Compare iShares Core High Dividend ETF (HDV) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares Core High Dividend ETF trades at $29.57 (market cap $15.11B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: iShares Core High Dividend ETF is far larger — about 15.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 118 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HDV | MRVI | |
|---|---|---|
Market Cap | $15.11B | $972.90M |
Volume | 2,559,662 | 4,325,710 |
52-Week High | $29.93 | $9.00 |
52-Week Low | $23.64 | $2.83 |
Typical Hold Time | 118 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $29.15, up 0.28% with a bullish technical signal from moving averages. The ETF recently underwent a significant sector rebalance, reducing healthcare exposure while increasing energy, staples, and utilities. Technical indicators show strong momentum with RSI at 66.71 suggesting neutral conditions, while ADX readings indicate a strong trend. Recent dividend distributions of $0.10 and $0.06 demonstrate the fund's income-focused strategy.
The ETF's concentrated sector allocation (62% in three sectors) presents both opportunity and risk. While the 3% yield attracts income investors, the reduced diversification may increase vulnerability to sector-specific headwinds. Technical strength supports near-term upside, but investors should weigh the trade-off between current income and long-term growth potential given the sector concentration.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
